Prot #CYTB323K12201: A Phase II, Multi-Part, Three-Year, Randomized, Open-Label, Assessor-Blinded, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants with Severe R

Project: Research project

Project Details

StatusActive
Effective start/end date4/10/243/31/30

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CYTB323K12201)